Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia

Chih Chun Lin, William G. Ondo

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Although VMAT2-inhibitors are now established as first-line treatment for tardive dyskinesia, not all patients respond to, or tolerate them. Numerous other agents have been adopted to treat tardive dyskinesia, but with variable results and generally lower quality methodologic reports. Amantadine is the most promising but benzodiazepines, branched chain neutral amino acids, Vitamin B6, several nutraceuticals, and botulinum toxin injections might help some patients. In all cases, better placebo controlled trials are needed before definitive recommendations can be made.

Original languageEnglish (US)
Pages (from-to)48-54
Number of pages7
JournalJournal of the Neurological Sciences
Volume389
DOIs
StatePublished - Jun 15 2018

Keywords

  • Drug-induced dyskinesia
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia'. Together they form a unique fingerprint.

Cite this